A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma

The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced hepatocellular carcinoma.
YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research suggests that YIV-906 could act to enhance the body's immune response to fight cancer and increase the anti-tumor activity of sorafenib and protect and repair the gastrointestinal tract by reducing inflammation and promoting tissue regeneration.
Inspired by a 1,800-year-old traditional medicine still in use today, YIV-906 is a botanical drug candidate, composed of an extract of four herbs and administered in oral capsule form.
The CALM (Combination of YIV-906 and Sorafenib to treat Advanced Liver cancer in a Multi-center study) trial is a multi-regional, randomized, placebo-controlled study.

开始日期2020-01-10

申办/合作机构

Yiviva, Inc.

NCT02178644

/ Completed临床1期IIT

Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer

This pilot study focuses on KD018 and will investigate the effect of this agent on reducing the Gastrointestinal (GI) toxicity associated with combined modality therapy of locally-advanced rectal cancer.

开始日期2014-07-01

申办/合作机构

Yale University

NCT00730158

/ Completed临床2期IIT

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

The proposed plan will investigate the mechanism and efficacy of Chinese herbal medicine as an adjunct to chemotherapy in treatment of patients with metastatic colorectal cancer. Our rationale for the therapeutic use of KD018 is its potential activity in reducing chemotherapy-induced toxicity, especially diarrhea.

开始日期2008-12-01

申办/合作机构

University of Pittsburgh

[+1]

100 项与 YIV-906 相关的临床结果

登录后查看更多信息

100 项与 YIV-906 相关的转化医学

登录后查看更多信息

100 项与 YIV-906 相关的专利（医药）

登录后查看更多信息

项与 YIV-906 相关的文献（医药）

2025-09-01·JOURNAL OF CHROMATOGRAPHY A

Interpreting metabolic profiling of YIV906 in vivo: A Synergistic strategy combining LC–HRMS-based molecular networking and metabolomics thought integration

Article

作者: Lian Zhu ; Yung-Chi Cheng ; Ci Yang ; Aiping Tian ; Shwu-Huey Liu ; Liangyin Shu ; Kailin Li ; Wei Cai ; Qing Li

The components can be transformed into various metabolites that exert pharmacological effects under the action of gut microbiota and drug-metabolizing enzymes after administration of traditional Chinese medicine (TCM). However, the comprehensive characterization of herbal compounds in vivo is still an important challenge due to the interference of endogenous compounds. In this study, an integrated strategy was built to illustrate the metabolic profiling of YIV906 (PHY906), a standardized botanical cancer drug candidate originated from Huangqin Tang in vivo by combining multivariate statistical analysis and feature based molecular networking (FBMN) based on UHPLC-Q-Exactive orbitrap mass spectrometry. Firstly, a multivariate statistical analysis method was used to screen differential components on account of metabolomics approach. Meanwhile, the self-build database was built to preliminarily screen prototype components and then operated in the Compound Discoverer software to accelerate the discovery of metabolites based on Biotransformation module. Furthermore, a FBMN was constructed on the Global Natural Product Social (GNPS) platform to accurately annotate compound structures and infer unknown metabolites according to the differences of MS² spectra and m/z value with adjacent nodes. Finally, a total of 63 prototype components and 180 metabolites including flavonoid, organic acid, monoterpenoid, triterpenoid and alkaloid were successfully identified in rat plasma and tissues based on the established strategy, as well as revealed the tissue distribution characteristics of main components. In conclusion, this study demonstrated an effective and practical strategy that enables the in-depth metabolic profiling of complex biological samples.

2024-06-01·Journal of Gastrointestinal Oncology

A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer

Article

作者: Liu, Shwu-Huey ; Higgins, Susan A ; Lam, Wing ; Hochster, Howard ; Zaheer, Wajih ; Cheng, Yung-Chi ; Johung, Kimberly L ; Kortmansky, Jeremy ; Lacy, Jill ; Verma, Nipun ; Stein, Stacey ; Cecchini, Michael ; Reddy, Vikram

Background:

Pre-operative chemoradiation for rectal cancer is often associated with severe gastrointestinal (GI) toxicity which can interrupt, delay, and/or lead to termination of treatment. In this study, we evaluated whether the addition of YIV-906, a novel herbal medicine proven to reduce GI toxicity associated with chemotherapy could also reduce GI side effects during standard pre-operative capecitabine and pelvic radiation therapy (RT) in the neoadjuvant setting for the treatment of locally advanced rectal cancer.

Methods:

This single arm clinical study enrolled 24 patients between Dec 23, 2014-Sep 17, 2018 at Smilow Cancer Hospital, a comprehensive cancer center at Yale New Haven Hospital. All patients were age ≥18 years, Eastern Cooperative Oncology Group 0-1 and with histologically confirmed T3-T4 and N0-N2, M0 adenocarcinoma of the rectum. Median follow-up was 61.9 months. All patients received concurrent pelvic external beam RT (50.4 Gy in 28 fractions), YIV-906 (taken orally 800 mg twice daily on days 1-4 of RT each week), and oral capecitabine delivered in a neo-adjuvant fashion, followed by definitive surgery. Toxicity was assessed weekly during radiation and until acute symptoms resolved and then at 28 days, 4 months, 7 months and 10 months. Toxicities were graded in accordance with Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Results:

At the time of surgery, 4 patients (16.7%) had a complete or near-complete response. At a median follow-up of 61.9 months, the mean overall survival (OS) of our patient cohort was 74.9 months [95% confidence interval (CI): 67.3-82.5]. The estimated 5-year OS was 82.0%. We observed 0% acute grade 4 toxicities, and only two cases of acute grade 3 diarrhea (8.3%).

Conclusions:

The addition of YIV-906 to capecitabine based chemoradiation for locally advanced rectal cancer led to reduced rates of GI toxicity compared to historical controls, in particular grade 3 or greater diarrhea. These findings suggest YIV-906 should be evaluated in a randomized clinical trial to further assess potential reductions in the toxicity profile of chemoradiation for GI cancers.

2020-09-30·Bioscience reports4区 · 生物学

WGCNA reveals key gene modules regulated by the combined treatment of colon cancer with PHY906 and CPT11

4区 · 生物学

Article

作者: Hu, Kaiwen ; Sun, Tao ; Wang, Yafei ; Wang, Fen ; Li, Quanwang ; Xing, Shuqin

Abstract:

Irinotecan (CPT11) is one of the most effective drugs for treating colon cancer, but its severe side effects limit its application. Recently, a traditional Chinese herbal preparation, named PHY906, has been proved to be effective for improving therapeutic effect and reducing side effects of CPT11. The aim of the present study was to provide novel insight to understand the molecular mechanism underlying PHY906-CPT11 intervention of colon cancer. Based on the GSE25192 dataset, for different three treatments (PHY906, CPT11, and PHY906-CPT11), we screened out differentially expressed genes (DEGs) and constructed a co-expression network by weighted gene co-expression network analysis (WGCNA) to identify hub genes. The key genes of the three treatments were obtained by merging the DEGs and hub genes. For the PHY906-CPT11 treatment, a total of 18 key genes including Eif4e, Prr15, Anxa2, Ddx5, Tardbp, Skint5, Prss12 and Hnrnpa3, were identified. The results of functional enrichment analysis indicated that the key genes associated with PHY906-CPT11 treatment were mainly enriched in ‘superoxide anion generation’ and ‘complement and coagulation cascades’. Finally, we validated the key genes by Gene Expression Profiling Interactive Analysis (GEPIA) and RT-PCR analysis, the results indicated that EIF4E, PRR15, ANXA2, HNRNPA3, NCF1, C3AR1, PFDN2, RGS10, GNG11, and TMSB4X might play an important role in the treatment of colon cancer with PHY906-CPT11. In conclusion, a total of 18 key genes were identified in the present study. These genes showed strong correlation with PHY906-CPT11 treatment in colon cancer, which may help elucidate the underlying molecular mechanism of PHY906-CPT11 treatment in colon cancer.

项与 YIV-906 相关的新闻（医药）

2025-07-10

·GlobeNewswire-Health Care

Yiviva Presents Phase 2b Results for YIV-906 in Combination with Sorafenib in Advanced Hepatocellular Carcinoma at ASCO and ESMO GI 2025

July 07, 2025 -- Yiviva, a clinical-stage biotechnology company pioneering systems biology-driven therapeutics, announced data from its multi-regional, randomized, double-blind, placebo-controlled Phase 2b study of sorafenib (SORA) with or without YIV-906 in advanced hepatocellular carcinoma (HCC) patients with chronic hepatitis B (HBV+). Results were highlighted in an American Society of Clinical Oncology (ASCO) Annual Meeting (May 30-June 3) abstract and presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress 2025 (July 2-July 5) poster. Presented by Dr. Ghassan Abou-Alfa MD, JD, MBA, PhD(hc), medical oncologist at Memorial Sloan Kettering Cancer Center, the study demonstrated improvements in both efficacy and tolerability for patients treated with YIV-906 plus sorafenib versus sorafenib monotherapy. 4.1 months vs. 3.5 months in the intention-to-treat (ITT) analysis Median Overall Survival (mOS): 14.3 months vs 7.5 months Median Time to Tumor Progression (mTTP): 5.59 months vs. 2.33 months Safety and Tolerability: Patients on the YIV-906 arm patients demonstrated greater duration of treatment exposure and continuation and were able to remain on treatment longer More than 250 GI (liver, pancreatic, colorectal, rectal) cancer patients treated in YIV-906 clinical studies have demonstrated proof-of-concept efficacy and safety. YIV-906 is a novel multi-targeted modality developed using a systems biology approach. YIV-906 increases the therapeutic index by acting as an immunomodulator in the tumor microenvironment (TME) and potentiating antitumor activity YIV-906 reprograms and primes the TME (STING, IFNg, IFNb, P-IRF3) and enhances innate immunity by polarizing and increasing M1 like macrophage infiltration and enhancing apoptosis. YIV-906 enhances adaptive immunity by promoting T-cell activation (promoting NFAT, inhibiting SHP1 and SHP2), modulating immune checkpoints (PD1/PDL1), reducing immune tolerance (by suppressing IDO), YIV-906 increases safety and reduces non-hematological toxicities by cytoprotecting the gastrointestinal tract by reducing GI inflammation (NF-kB, COX2, iNOS, IL-6), promoting damaged tissue repair (Wnt pathway), and reducing pain (NK1). “These results demonstrate the obligation to further study YIV-906’s potential to benefit hepatocellular carcinoma patients with hepatitis B who have limited treatment options,” said co-principal investigator Prof. Dr. Ghassan Abou-Alfa. “YIV-906 could broaden the therapeutic index and improve efficacy, safety and tolerability, and merits further clinical exploration with other studies and standards-of-care as a potential new treatment modality and paradigm.” The Phase 2b study (NCT04000737) randomized (2:1) patients (n=62) with treatment-naïve, advanced HBV-positive HCC, Child-Pugh A, BCLC Stage B or C, and ECOG ≤1 to either the YIV-906 + sorafenib arm or the placebo + sorafenib arm. Patients were enrolled in multiple regions (United States, Mainland China, Hong Kong, Taiwan) and the study was conducted from January 2020 to November 2024. The primary endpoint was progression free survival (PFS); secondary endpoints included overall survival (OS), time to progression (TTP), objective response rate (ORR), diseases control rate (DCR), safety and tolerability, and quality of life (QoL). More detailed information is available through 2025 ASCO Abstract # e16244 and ESMO GI Poster #P172. The study was sponsored by Yiviva with grant support from the Henry Bronson Endowment of Yale University, National Foundation for Cancer Research, Asian Fund for Cancer Research, and China 13-5 National Major Scientific and Technological Special Project for Significant New Drug Development. YIV-906 (formerly known as PHY906 or KD018) is a patented, orally administered investigational drug that acts as a pan-adjuvant improving the efficacy and safety for a broad spectrum of cancer drugs and regimens (including chemotherapies, immunotherapies, radiation, and cell therapies). YIV-906 has been studied in nine clinical trials in solid tumors (hepatocellular carcinoma, pancreatic cancer, colorectal cancer, and rectal cancer) with data demonstrating the potential for YIV-906 to improve overall survival and/or progression-free survival and reduce non-hematological toxicities (including diarrhea, nausea, vomiting, fatigue, and hand-foot syndrome). YIV-906 was inspired by an 1800-year-old traditional medicine and is being developed under the United States Food and Drug Administration’s (FDA) botanical drug regulatory pathway. The FDA has granted YIV-906 two Orphan Drug Designations (ODD) for the treatment of hepatocellular carcinoma and pancreatic cancers. Yiviva is committed to developing innovative medicines using a multi-targeted systems biology approach to improve survival and quality of life for patients with cancer and other serious diseases. The platform biotechnology company was launched with Yale University and Henry Bronson Professor of Pharmacology and Medicine Yung-Chi Cheng as co-founders, with teams in the United States and Asia. The content above comes from the network. if any infringement, please contact us to modify.

临床结果孤儿药ASCO会议免疫疗法

2024-08-13

·drugs

Chinese Botanical Medicine Eases a Cancer Treatment Side Effect

TUESDAY, Aug. 12, 2024 -- An experimental drug based on ancient Chinese herbal medicine can help ease the toxic side effects of chemotherapy and radiation therapy in cancer patients, the results of a small new trial results suggest. A small group of 24 patients experienced fewer GI side effects from their treatment for rectal cancer after they took YIV-906, researchers reported recently in the Journal of Gastrointestinal Oncology . YIV-906 is based on an 1,800-year-old treatment for stomach ailments that combined licorice, dates, peonies and skullcap, researchers said. “This study is the first demonstration of YIV-906’s effectiveness in reducing GI toxicity caused by chemotherapy and radiation, showing the medicine’s potential of improving the patient’s quality of life while increasing treatment effectiveness,” said co-researcher Yung-Chi Cheng , a professor of pharmacology at Yale School of Medicine who helped develop the drug. For the four-year, phase 2 study, the patients were given capsules of YIV-906 along with chemo and radiation prior to surgery. At the time of surgery, about 17% of patients had a complete or near-complete response to their cancer treatment, while the overall survival rate at five years was 82%, results show. Only two cases of severe diarrhea were reported among the patients. YIV-906 is meant to ease side effects like diarrhea, fatigue and nausea. “We didn’t have any serious toxicity associated with the drug and patients found taking the drug in pill form very easy and tolerable,” senior researcher Dr. Susan Higgins , a professor of therapeutic radiology and of obstetrics, gynecology, and reproductive sciences at Yale. The results warrant further testing of YIV-906 in more patients with other types of cancer, such as pelvic cancer, researchers said in a Yale new release. People taking YIV-906 might be able to withstand harsher doses of both chemo and radiation therapy, making their cancer treatment more effective, the researchers added. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果放射疗法临床2期

2024-02-05

·GlobeNewswire-Health Care

Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach

NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding (MOU) with AstraZeneca China to establish a research and development collaboration at AstraZeneca’s Innovation Campus (iCampus) in Chengdu, China. The signing ceremony took place at the 2023 China International Import Expo (CIIE) at the National Exhibition and Convention Center in Shanghai. To address global unmet medical needs, Together Yiviva and AstraZeneca China will jointly build platforms for scientific research transformation and industrial development led by academicians and experts with the aim to modernize botanical medicines in accordance with new regulatory pathways for botanical medicines by the United States Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA). “2023 marks the 30th anniversary of AstraZeneca in China. In collaboration with the Chengdu government and Chengdu High-Tech Industrial Zone (CDHT), AstraZeneca is establishing a modern healthcare development platform integrating traditional Chinese medicine and Western medicine. At CIIE, AstraZeneca announced plans to further globalize Chinese medicine. Our strategic partnership with Yiviva, will advance our blueprint for how to develop innovative medicines inspired by Chinese medicine,” remarked Lily Zhu, Vice President of AstraZeneca China and Head of DCI and CSE. “Disease knows no borders. By bringing together the knowledge and best practices of Western and Eastern Medicine, WE Medicine, we can learn from ancient wisdom to develop future medicines. Together with AstraZeneca China’s expertise, ecosystem, and resources, and Yiviva’s team, platform technologies, and pipeline, we can pioneer a new paradigm for systems biology drug development to address global unmet medical needs,” said Peikwen Cheng, Co-Founder and CEO of Yiviva. About Yiviva’s Platforms and Pipeline in Oncology Yiviva’s STAR (signal transduction, activity and response) drug discovery platform accelerates the identification of botanical therapeutics that influence immune function, inflammatory responses, cell growth, metabolic functions, and hormone activity. Through STAR, Yiviva can design sophisticated multi-target drugs that map to complicated disease biology. Yiviva has discovered six first-in-class drug candidates to treat cancer and inflammatory diseases. Yiviva applies patented, mechanism-based quality control linked to biological activity to manufacture batch-to-batch consistent drug product that satisfies established regulatory requirements for complex products. Yiviva’s lead candidate drug YIV-906 is a proprietary extract of 4 medicinal plants, inspired by an 1800-year-old traditional Chinese medicine formula. YIV-906 acts as an immunomodulator in the tumor microenvironment, turning cold tumors hot and potentiating anti-tumor activity for chemotherapies, immunotherapies, cell therapies, or radiation therapies; and acts as a cytoprotector in the gastrointestinal tract, reducing non-hematological toxicities and speeding up damaged tissue recovery. Yiviva has conducted 8 early-stage clinical trials in solid tumors (hepatocellular carcinoma, pancreatic cancer, colorectal cancer, and rectal cancers), with promising data suggesting that YIV-906 could prolong survival and improve quality of life. Yiviva recently recruited its last-patient-in in a first-line, randomized, double-blinded Phase 2b study of sorafenib plus YIV-906 in the treatment of hepatocellular carcinoma patients with hepatitis B. The CALM study is a multi-regional trial in the United States, Mainland China, Hong Kong, and Taiwan and expects a data readout in 2024. Yiviva recently published preclinical data conducted at Yale University about its novel therapeutic YIV-818-A to treat prostate cancer. YIV-818-A acts through multiple mechanisms, including androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation and could help overcome drug resistance to prostate cancer and could enhance apalutamide, darolutamide, or enzalutamide efficacy. About Yiviva Yiviva is a clinical stage, platform biotechnology company developing systems biology medicines to prevent, treat, and/or cure aging-related diseases, including cancer and inflammatory diseases. The company was launched with Yale University and Henry Bronson Professor of Pharmacology and Medicine Yung-Chi Cheng as co-founders, with teams in the United States and Greater China. Yiviva’s investors include the National Foundation for Cancer Research and the Asian Fund for Cancer Research. For further information, please visit https://yiviva.com. About AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. Contact:Email: hello@yiviva.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8d78fdf0-e819-4a98-abe1-3944978b9ad8

临床2期免疫疗法

100 项与 YIV-906 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床2期	美国	Yale University	2022-06-15
晚期肝细胞癌	临床2期	美国	Yiviva, Inc.	2020-01-10
晚期肝细胞癌	临床2期	中国	Yiviva, Inc.	2020-01-10
晚期肝细胞癌	临床2期	中国香港	Yiviva, Inc.	2020-01-10
晚期肝细胞癌	临床2期	中国台湾	Yiviva, Inc.	2020-01-10
转移性结直肠癌	临床2期	美国	Kadmon Corp. LLC	2008-12-01
转移性胰腺腺癌	临床2期	美国	PhytoCeutica, Inc.	2006-12-01
转移性胰腺腺癌	临床2期	美国	Roche Pharma AG	2006-12-01
不可切除的肝细胞癌	临床2期	美国	PhytoCeutica, Inc.	2003-10-01
不可切除的肝细胞癌	临床2期	中国台湾	PhytoCeutica, Inc.	2003-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04000737 (ESMO_GI2025) 人工标引	临床2期	肝细胞癌辅助 HBV(+)	107	Sorafenib + YIV-906	淵膚夢繭淵鬱衊窪鬱鬱(襯膚獵憲選鏇膚窪糧艱) = 鏇憲糧築願繭憲衊餘糧鑰鑰簾範積膚壓獵膚顧 (構鏇鹹壓膚齋鹽蓋鏇繭 ) 更多	积极	2025-07-03
				Placebo+Sorafenib	淵膚夢繭淵鬱衊窪鬱鬱(襯膚獵憲選鏇膚窪糧艱) = 顧獵遞獵鹽繭膚鏇襯醖鑰鑰簾範積膚壓獵膚顧 (構鏇鹹壓膚齋鹽蓋鏇繭 ) 更多
NCT04000737 (International phase II randomized placebo-controlled study, ASCO2025)	临床2期	晚期肝细胞癌一线 HBV (+)	107	YIV-906 + Sorafenib	構鹽獵膚壓窪積獵淵願(鹽範鹹憲鬱窪顧築醖夢) = improvement was also observed by the investigator 製餘積願膚糧簾鑰衊積 (鹹夢艱範顧窪衊積獵獵 ) 更多	积极	2025-05-30
				Placebo
NCT00730158 (CTgov)	临床2期	转移性结直肠癌	33	Irinotecan+KD018 (Arm A - Irinotecan + KD018)	襯窪餘顧範餘築窪鹹衊 = 鑰夢糧繭襯積積築製餘壓壓鑰鏇夢鹽構壓遞鏇 (繭觸壓獵憲範製觸構構, 獵願獵膚製糧醖範膚觸 ~ 襯鹽醖簾淵選憲窪範膚) 更多	-	2019-05-22
				Placebo+Irinotecan (Arm B - Irinotecan + Placebo)	襯窪餘顧範餘築窪鹹衊 = 範遞鹹鏇夢積獵膚衊夢壓壓鑰鏇夢鹽構壓遞鏇 (繭觸壓獵憲範製觸構構, 窪觸膚齋膚築鬱網壓餘 ~ 夢製艱淵積鑰窪願壓鹽) 更多
NCT00411762 (CTgov)	临床1/2期	转移性胰腺腺癌 \| 胰腺癌	25	Capecitabine+PHY906	糧衊顧憲鑰鬱餘夢鏇鹹(觸構鹽簾繭網繭積繭膚) = 觸鬱願膚觸廠鏇願醖顧積襯獵選顧製廠淵餘鬱 (範壓願餘網齋鏇鬱壓簾, 齋憲襯顧鬱觸構簾構範 ~ 構選範壓遞網繭齋齋淵) 更多	-	2015-03-27
Pubmed \| Cancer Chemother Pharmacol	临床2期	胰腺癌二线	25	Capecitabine + PHY906	糧範窪觸醖鏇範選醖襯(顧鹽範襯憲齋淵獵簾襯) = 築範淵顧憲構醖築膚觸艱遞憲觸窪簾餘夢醖膚 (衊齋艱醖願窪淵築繭網 ) 更多	-	2014-02-01
ASCO2010	临床2期	胰腺癌	25	PHY906 plus capecitabine (CAP)	窪壓鏇選淵廠積鏇壓鏇(獵糧艱醖網製鹽廠夢糧) = 夢糧襯齋鬱窪糧築網選鏇製網淵獵窪憲鬱廠積 (鏇選獵艱壓積鑰網醖淵 ) 更多	-	2010-05-20
NCT04000737 (Pubmed)	临床1/2期	晚期肝细胞癌	-	PHY906	築獵醖網範餘願製遞遞(獵廠顧網壓鹹壓鬱選鹽) = 蓋網壓壓鑰網襯選鹹鹹遞選選齋糧觸顧壓鏇廠 (糧築鹽積鹽願壓製衊顧 ) 更多	-	2009-10-01
ASCO2009	N/A	胃肠道肿瘤	44	PHY906	簾積膚製夢積願夢網膚(蓋製願範獵鬱製觸鹹鑰) = 醖製願艱膚構鹹鬱繭醖鬱壓夢積憲選蓋顧製範 (鹽鹹顧構壓壓願膚窪觸 )	-	2009-05-20
				CAP alone	簾積膚製夢積願夢網膚(蓋製願範獵鬱製觸鹹鑰) = 蓋衊網鑰構鬱鏇鏇淵遞鬱壓夢積憲選蓋顧製範 (鹽鹹顧構壓壓願膚窪觸 )
ASCO2007	临床1/2期	肝细胞癌	18	PHY906 + Capecitabine 1000 mg/m2 BID	餘願網積醖網鏇製艱積(製醖範衊願廠壓鑰鏇觸) = 餘鹽襯憲糧衊觸蓋窪鑰鹽襯顧蓋鏇範窪獵襯範 (獵積簾繭糧鬱選襯遞夢 ) 更多	-	2007-06-20
				PHY906 + Capecitabine 750 mg/m2 BID	餘願網積醖網鏇製艱積(製醖範衊願廠壓鑰鏇觸) = 鹹夢艱範壓鑰鏇淵範獵鹽襯顧蓋鏇範窪獵襯範 (獵積簾繭糧鬱選襯遞夢 ) 更多